Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study
Abstract The management of Type-2 Diabetes Mellitus (T2DM) remains challenging in cases of poor glycemic control despite triple Oral Hypoglycemic Agent (OHA) therapy. This prospective cohort study aimed to assess the effectiveness of Empagliflozin as part of a quadruple OHA regimen over a 7-year fol...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-84993-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544786384781312 |
|---|---|
| author | Fatemeh Moosaie Shiva Abedinzadeh Soghra Rabizadeh Kimia Daneshvar Mohammadamin Noorafrooz Fatemeh Alsadat Mojtahedi Niloofar Deravi Seyede Marzie Fatemi Abhari Akam Ramezani Alipasha Meysamie Marzieh Hajibabaei Sahar Karimpour Reyhan Mahsa Abbaszadeh Manouchehr Nakhjavani Alireza Esteghamati |
| author_facet | Fatemeh Moosaie Shiva Abedinzadeh Soghra Rabizadeh Kimia Daneshvar Mohammadamin Noorafrooz Fatemeh Alsadat Mojtahedi Niloofar Deravi Seyede Marzie Fatemi Abhari Akam Ramezani Alipasha Meysamie Marzieh Hajibabaei Sahar Karimpour Reyhan Mahsa Abbaszadeh Manouchehr Nakhjavani Alireza Esteghamati |
| author_sort | Fatemeh Moosaie |
| collection | DOAJ |
| description | Abstract The management of Type-2 Diabetes Mellitus (T2DM) remains challenging in cases of poor glycemic control despite triple Oral Hypoglycemic Agent (OHA) therapy. This prospective cohort study aimed to assess the effectiveness of Empagliflozin as part of a quadruple OHA regimen over a 7-year follow-up period in 575 adult patients with uncontrolled T2DM on a triple OHA regimen and who were unwilling to initiate insulin therapy. Overall, 92.5% of patients achieved their target HbA1c levels. Significant reductions were observed in all glycemic parameters after 68 months (p < 0.001). Weight and BMI significantly decreased, whereas waist circumference remained unchanged. Lipid profiles showed significant improvements in total cholesterol, LDL, and triglycerides, while HDL levels did not change significantly. Blood pressure trends revealed significant reductions in both diastolic blood pressure (DBP) and mean arterial pressure (MAP), though systolic blood pressure (SBP) remained relatively stable. Our study indicates that adding empagliflozin to a drug regimen consisting of multiple OHAs can effectively control glycemia in T2DM patients with more pronounced target achievement (< 7%) and HbA1c reduction along with improvement in cardiometabolic parameters, suggesting its potential as a promising alternative for long-term glycemic management. |
| format | Article |
| id | doaj-art-e818220054254e0a8892454a6092363e |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-e818220054254e0a8892454a6092363e2025-01-12T12:18:49ZengNature PortfolioScientific Reports2045-23222025-01-0115111210.1038/s41598-024-84993-xEmpagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort studyFatemeh Moosaie0Shiva Abedinzadeh1Soghra Rabizadeh2Kimia Daneshvar3Mohammadamin Noorafrooz4Fatemeh Alsadat Mojtahedi5Niloofar Deravi6Seyede Marzie Fatemi Abhari7Akam Ramezani8Alipasha Meysamie9Marzieh Hajibabaei10Sahar Karimpour Reyhan11Mahsa Abbaszadeh12Manouchehr Nakhjavani13Alireza Esteghamati14Endocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical SciencesEndocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical SciencesEndocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical SciencesEndocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical SciencesEndocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical SciencesEndocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical SciencesEndocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical SciencesDepartment of Pediatrics, Imam Ali Hospital, Alborz University of Medical SciencesEndocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical SciencesDepartment of Community Medicine, Tehran University of Medical SciencesPsychosomatic Medicine Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical SciencesEndocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical SciencesEndocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical SciencesEndocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical SciencesEndocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical SciencesAbstract The management of Type-2 Diabetes Mellitus (T2DM) remains challenging in cases of poor glycemic control despite triple Oral Hypoglycemic Agent (OHA) therapy. This prospective cohort study aimed to assess the effectiveness of Empagliflozin as part of a quadruple OHA regimen over a 7-year follow-up period in 575 adult patients with uncontrolled T2DM on a triple OHA regimen and who were unwilling to initiate insulin therapy. Overall, 92.5% of patients achieved their target HbA1c levels. Significant reductions were observed in all glycemic parameters after 68 months (p < 0.001). Weight and BMI significantly decreased, whereas waist circumference remained unchanged. Lipid profiles showed significant improvements in total cholesterol, LDL, and triglycerides, while HDL levels did not change significantly. Blood pressure trends revealed significant reductions in both diastolic blood pressure (DBP) and mean arterial pressure (MAP), though systolic blood pressure (SBP) remained relatively stable. Our study indicates that adding empagliflozin to a drug regimen consisting of multiple OHAs can effectively control glycemia in T2DM patients with more pronounced target achievement (< 7%) and HbA1c reduction along with improvement in cardiometabolic parameters, suggesting its potential as a promising alternative for long-term glycemic management.https://doi.org/10.1038/s41598-024-84993-xDiabetes mellitus, type 2Drug therapy, QuadrupleHypoglycemic agents |
| spellingShingle | Fatemeh Moosaie Shiva Abedinzadeh Soghra Rabizadeh Kimia Daneshvar Mohammadamin Noorafrooz Fatemeh Alsadat Mojtahedi Niloofar Deravi Seyede Marzie Fatemi Abhari Akam Ramezani Alipasha Meysamie Marzieh Hajibabaei Sahar Karimpour Reyhan Mahsa Abbaszadeh Manouchehr Nakhjavani Alireza Esteghamati Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study Scientific Reports Diabetes mellitus, type 2 Drug therapy, Quadruple Hypoglycemic agents |
| title | Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study |
| title_full | Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study |
| title_fullStr | Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study |
| title_full_unstemmed | Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study |
| title_short | Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study |
| title_sort | empagliflozin based quadruple oral therapy for type 2 diabetes a prospective cohort study |
| topic | Diabetes mellitus, type 2 Drug therapy, Quadruple Hypoglycemic agents |
| url | https://doi.org/10.1038/s41598-024-84993-x |
| work_keys_str_mv | AT fatemehmoosaie empagliflozinbasedquadrupleoraltherapyfortype2diabetesaprospectivecohortstudy AT shivaabedinzadeh empagliflozinbasedquadrupleoraltherapyfortype2diabetesaprospectivecohortstudy AT soghrarabizadeh empagliflozinbasedquadrupleoraltherapyfortype2diabetesaprospectivecohortstudy AT kimiadaneshvar empagliflozinbasedquadrupleoraltherapyfortype2diabetesaprospectivecohortstudy AT mohammadaminnoorafrooz empagliflozinbasedquadrupleoraltherapyfortype2diabetesaprospectivecohortstudy AT fatemehalsadatmojtahedi empagliflozinbasedquadrupleoraltherapyfortype2diabetesaprospectivecohortstudy AT niloofarderavi empagliflozinbasedquadrupleoraltherapyfortype2diabetesaprospectivecohortstudy AT seyedemarziefatemiabhari empagliflozinbasedquadrupleoraltherapyfortype2diabetesaprospectivecohortstudy AT akamramezani empagliflozinbasedquadrupleoraltherapyfortype2diabetesaprospectivecohortstudy AT alipashameysamie empagliflozinbasedquadrupleoraltherapyfortype2diabetesaprospectivecohortstudy AT marziehhajibabaei empagliflozinbasedquadrupleoraltherapyfortype2diabetesaprospectivecohortstudy AT saharkarimpourreyhan empagliflozinbasedquadrupleoraltherapyfortype2diabetesaprospectivecohortstudy AT mahsaabbaszadeh empagliflozinbasedquadrupleoraltherapyfortype2diabetesaprospectivecohortstudy AT manouchehrnakhjavani empagliflozinbasedquadrupleoraltherapyfortype2diabetesaprospectivecohortstudy AT alirezaesteghamati empagliflozinbasedquadrupleoraltherapyfortype2diabetesaprospectivecohortstudy |